Last reviewed · How we verify
Omega 3 fatty acid
At a glance
| Generic name | Omega 3 fatty acid |
|---|---|
| Also known as | Omega 3, OmegaD Softgels, Eicosapentaenoic acid (EPA) / docosahexaenoic acid (DHA), Ω-3 fatty acids, LOVAZA |
| Sponsor | Rodolfo Alejandro |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Heart & Health Study (NA)
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting Conditions (NA)
- OMEGA - Dietary Intervention - COPD Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega 3 fatty acid CI brief — competitive landscape report
- Omega 3 fatty acid updates RSS · CI watch RSS
- Rodolfo Alejandro portfolio CI